

**Amendment to the Specification**

Please amend page 25 of the specification to correct a typographical error. The word "insoubilized" at line 8 should read "insolubilized". Also, please amend page 40 of the specification to read at line 21, "human prostate cancer PC3" instead of "human pancreatic cancer PC3". Support for this amendment can be found, for example, in Fig. 1E.

**REMARKS**

Upon entry of this Amendment, Claims 1, 4-13, 17-19, 23-25, 30-61 will be pending. Claims 1, 4, 5, 6, 10, 17, 23 and 30 have been amended to more clearly define the present invention. Claims 2, 3, and 14-16 have been withdrawn without prejudice or disclaimer. New claims 31-61 have been added.

Claims 6, 10 and 23 were amended to recite that the antisense oligonucleotide comprises at least 15 consecutive nucleotides. Support for the amendments can be found throughout the specification as filed.

Claims 6 and 10 were further amended to recite that the tumor is a carcinoma. Support for this amendment can be found in Examples 1 to 4, and in Figures 1(a to f), 2(a and b), 3 and 4.

New Claim 31 specifies an oligonucleotide of 20 to about 100 nucleotides in length. Support may be found throughout the specification as filed.

New Claim 32 specifies an oligonucleotide that consists of a sequence selected from the group of SEQ ID Nos: 1-30. Support may be found on page 16, Table 1.